BLLN
BillionToOne, Inc.
September 30, 2026 · market open
- Rarity
- 1.77
- Peak move
- −10.44%
- Float cap
- $2.3B
BillionToOne is a molecular diagnostics company that uses a single-molecule next-generation sequencing platform to detect and quantify genetic targets in cell-free DNA from a blood draw. It develops prenatal tests, including UNITY for fetal risk assessment, and oncology liquid biopsy tests, Northstar Select and Northstar Response, for therapy selection and treatment monitoring. Its tests are sold to physicians, clinics, and healthcare providers to guide patient care.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 4 from SEC or newswire · 0 timed with the movepeer_disclosureGene Solutions announced publication in AJOG Global Reports of a study showing first-trimester NIPT cell-free DNA fragmentomic end-motif patterns predict spontaneous preterm birth with AUC 0.970 and 94% sensitivity at >90% specificity.
insider_saleBillionToOne CTO David Tsao sold 3,333 Class A shares at $125.00 for $416,625 on September 24, 2026, alongside an option exercise of 6,666 shares at $2.80, disclosed in a Form 4 filed Sept 28, 2026.
insider_saleBillionToOne SVP of Laboratory Operations John Roderick ten Bosch sold 1,416 Class A shares at $120.00 for $169,920 on September 24, 2026, leaving 22,219 shares directly held, per a Form 4 filed Sept 28, 2026.
SEC4 0002087126-26-000015Webs4.biz.itc.cninsider_saleA Form 144 filed Sept 28, 2026 shows the proposed sale of 2,666 Class A shares of BillionToOne (BLLN) worth $321,626.24 in the account of CEO Oguzhan Atay's spouse, via Fidelity under a Rule 10b5-1 plan dated June 7, 2026.
SEC144 0001959173-26-007122Webkalkine.cominsider_saleBillionToOne CEO/Chairman Oguzhan Atay filed notice to sell 8,333 Class A shares worth about $1,005,293 via Fidelity under a 10b5-1 plan, acquired that day through a stock option exercise, with prior sales including 24,999 shares on Sept 14.
SEC144 0001959173-26-007121Websec.gov